Skip to main content

Table 1 Monoclonal Antibodies in Clinical Trials

From: Biochemical prevention and treatment of viral infections – A new paradigm in medicine for infectious diseases

Product

Company

Disease

Status

MEDI-501

MedImmune

Genital Warts HPV

II

Nabi-HB

Nabi Biopharmaceuticals

Hepatitis B

Market

Ostavir

Protein Design Labs

Hepatitis B

II

XTL-002

XTL Biopharmaceuticals Ltd.

Hepatitis C

I

Civacir

Nabi Biopharmaceuticals

Hepatitis C

I/II

1F7 Antibody

Immune Network Ltd.

Hepatitis C, HIV/AIDS

Preclinical

PRO 140

Progenics Pharmaceuticals

HIV/AIDS

Preclinical

hNM01

AbNovo Inc., Immune Network Ltd.

HIV/AIDS

I

PRO 367

Roche Holding Progenics Pharmaceuticals

HIV/AIDS

I/II

TNX-355

Tanox, Inc., Biogen, Inc. (Massachusetts)

HIV/AIDS

I

OraQuick HIV-1

OraSure Technologies, Inc.

HIV/AIDS

Market

Cytolin

CytoDyn Amerimmune Pharmaceuticals, Inc.

HIV/AIDS

I/II

Tipranavir

TIPRANAVIR

HIV/AIDS

III

HXB

AAI International, AnaaiPharma Company

Herpes Simplex Virus type 2

Preclinical

MEDI-491

MedImmune

Human B19 parvovirus

I

Synagis™ (Palivizumab)

MedImmune

Respiratory Syncytial Virus

Approved in 1998

Numax

MedImmune

Respiratory Syncytial Virus

Preclinical

INS37217 Intranasal

Inspire Pharmaceuticals

Rhinovirus (common cold)

II